Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Sheffield table is useful …

  1. L E Ramsay, Professor,
  2. E J Wallis, Research assistant,
  3. I U Haq, Specialist registrar,
  4. R Williamson, Lecturer,
  5. W W Yeo, Senior lecturer,
  6. P R Jackson, Reader
  1. Clinical Pharmacology and Therapeutics, Royal Hallamshire Hospital, Sheffield S10 2JF
  2. Village Surgery, Talbot Village, Poole BH12 5BF
  3. Lipid Clinic, Royal Bournemouth General Hospital, Bournemouth BH7 7DW
  4. a For the hyperlipidaemia guidelines subcommittee, Dorset Clinical Outcomes and Audit Group

    EDITOR—Two letters last December on the use of statins, by Betteridge et al (p 1619) and Reynolds et al (p 1620), criticised the Sheffield table.1 The rate of coronary heart disease events targeted (3% per year) is not “arbitrarily high,” as Reynolds et al say, but was proposed after consideration of the number needed to treat, cost effectiveness, proportion of adults needing treatment, and total cost of treatment at different thresholds of risk of coronary heart disease.2 The European task force's guidelines3 which suggested the 2% per year threshold for coronary heart disease preferred by the letters' authors predated the statin trials.

    We do not accept that high risk people over age 65 should be denied treatment,1 and treating those below age 65 with a relative risk of coronary heart disease of 41 seems unwise. A 35 year old woman with a total cholesterol concentration of 7.0 mmol/l, systolic blood pressure of 160 mm Hg, and no other risk factors has a relative risk …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular